ArticleWorld journal of microbiology & biotechnology2026
Phenotypic and genomic insights into Stenotrophomonas sepilia SMBL8: metabolic versatility, antibiotic resistance and pathogenic potential.
Article in World journal of microbiology & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stenotrophomonas sepilia SMBL8 is a motile, hemolytic, Gram-negative environmental bacterium isolated from a polluted lake. S. sepilia, a recently identified member of the Stenotrophomonas maltophilia complex, has been reported in both clinical and environmental settings; however, it remains understudied. In this study, we comprehensively investigated the phenotypic and genomic characteristics, emphasising metabolic versatility, antibiotic resistance profile, and pathogenic potential. Antibiotic susceptibility testing revealed sensitivity to trimethoprim/sulphamethoxazole, levofloxacin, and minocycline; resistance and intermediate resistance to β-lactams, aminoglycosides, and chloramphenicol. Whole-genome sequencing revealed a genome length of 4,510,692 bp and a G + C content of 66.56%. Functional annotation revealed enrichment and abundant gene distribution in carbohydrate metabolism and binding activity essential for carbohydrate-active metabolism. Subsequent analysis identified a diverse carbohydrate-active enzyme repertoire with potential biotechnological applications as a biocatalyst for substrates such as xylan and chitin. Conversely, further genomic analysis revealed siderophore-encoding genes, multiple putative resistance genes, and mobile genetic elements, including prophages and genomic islands, that encode cascades of putative virulence-associated genes with G + C content distinct from the core genome, suggesting acquisition through horizontal gene transfer. In conclusion, our findings address an existing knowledge gap and highlight the potential dualistic nature of S. sepilia SMBL8, both as a beneficial industrial bacterium and an opportunistic pathogen, facilitated by metabolic versatility and genomic plasticity. Our study also emphasises the critical need for environmental surveillance in anthropogenically disturbed habitats to monitor and mitigate the potential emergence of resistant opportunistic pathogens.
Indexed as
Identifiers
42430049What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.